Cambridge Healthtech Institute’s Fourth Annual

Circulating Tumor Cells

Spotlight on Clinical Validation

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA

 

Day 1 | Day 2 | Day 3 | Download Brochure 

Wednesday, February 12

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

 

8:00 Plenary Keynote Session (Click Here For More Details) 


9:45 Refreshment Break and Poster Competition Winner Announced in the Exhibit Hall


EMERGING TECHNOLOGIES FOR CTC DETECTION AND ANALYSIS

10:35 Chairperson’s Remarks

Avraham Rasooly, Ph.D., Program Director, NCI NIH 

10:40 Isolation and Analysis of Individual Circulating Tumor Cells with eDAR

Daniel T. Chiu, Ph.D., A. Bruce Montgomery Professor of Chemistry & Bioengineering, University of Washington, Seattle

This presentation will describe a method we developed for isolating circulating tumor cells from peripheral blood, with emphasis on a set of probes that we have developed to enhance our ability to detect and isolate these rare cells. We will also describe the performance of this system, the downstream single-cell analysis we have performed, and its clinical utility.

11:10 High-Throughput CTC Capture, Sorting and Analysis Using a Velocity Valley Chip

Shana O. Kelley, Ph.D., Distinguished Professor, Chemistry, Biochemistry, Pharmaceutical Sciences, Biomedical Engineering, University of Toronto

A new device for CTC isolation and analysis will be described that allows separation of different CTC populations and integrated genetic analysis. The characterization of this device with clinical samples and a comparison with the gold standard for CTC analysis will be presented.

11:40 Aptamers and DNA Nanospheres for Isolation of Cancer Cells Using Microfluidic Devices

Z. Hugh Fan, Ph.D., Professor, Interdisciplinary Microsystems Group, Mechanical & Aerospace Engineering, Biomedical Engineering, Chemistry, University of Florida

We will present our results on incorporating DNA aptamers with microfluidic devices for the isolation of cancer cells from whole blood. The performance of aptamers will be compared with DNA nanospheres, each of which is comprised of a gold nanoparticle conjugated with a number of aptamers and is capable of multivalent binding with a cancer cell. Isolation and enumeration of circulating tumor cells (CTC) from pancreatic cancer patients will also be discussed.

12:10 pm Session Break

12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:00 Refreshment Break in the Exhibit Hall and Last Chance for Poster Viewing

1:40 Chairperson’s Remarks

Avraham Rasooly, Ph.D., Program Director, NCI NIH

1:45 Flexible Micro Spring Array Device (FMSA) for High-Throughput Enrichment of Viable Circulating Tumor Cells

Siyang Zheng, Ph.D., Assistant Professor, Bioengineering, Pennsylvania State University

The enrichment of viable CTCs for ex vivo analysis could further improve cancer diagnosis and guide treatment selection. The new flexible micro spring array (FMSA) device enriches viable CTCs independent of antigen expression. The FMSA device provides a versatile and reliable platform capable of viable enrichment and analysis of CTCs from clinically relevant volumes of whole blood.

2:15 Microfluidics for Characterization of Circulating Tumor Cells

Jiang F. Zhong, Ph.D., Assistant Professor, Pathology, University
of Southern California

Microfluidic devices for isolation and molecular characterization of single cells will be discussed.

2:45 Microencapsulated Sensors for Circulating Tumor Cell Detection

Weian Zhao, Ph.D., Professor, Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Chao Family Comprehensive Cancer Center, University of California, Irvine

This is a new platform technology that surpasses some of the challenges faced by current CTC detection systems including sensitivity, specificity, and throughput. It will be of broad interest to academia, industry and patient care.

3:15 Detection and Characterization of Viable Circulating Tumor Cells

Catherine Alix-Panabières, Ph.D., Maître de Conférence, Praticien Hospitalier, Associate Professor, Director, Laboratory of Rare Human Circulating Cells, Institute of Research in Biotherapy, Saint-Eloi Hospital, University Medical Centre of Montpellier

The enumeration and characterization of circulating tumor cells (CTCs) in the peripheral blood and disseminated tumor cells (DTCs) in bone marrow may provide important prognostic information and might help to monitor efficacy of therapy. Since current assays cannot distinguish between apoptotic and viable DTCs/CTCs, it is now possible to apply a novel ELISPOT assay (designated ‘EPISPOT’) that detects proteins secreted/released/shed from single epithelial cancer cells.

3:45 Refreshment Break


NEW DEVICES

4:00 Chairperson’s Remarks

Steven A. Soper, Ph.D., Biomedical Engineering, Chemistry; William H. Pryor Emeritus Professor, Director, Center for BioModular Multi-Scale Systems, University of North Carolina, Chapel Hill

4:05 MicroHall Sensor for Direct CTC Detection and Profiling in Blood

Hakho Lee, Ph.D., Assistant Professor, Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School

This presentation will describe a novel, chip-based magnetic cytometer that can detect and molecularly profile CTCs directly from patient samples.

4:35 Measuring Physical Properties of Circulating Tumor Cells

Scott R. Manalis, Ph.D., Professor, Biological Engineering, Massachusetts Institute of Technology

My lab is developing microfluidic approaches for measuring multiple physical properties of single cells with high precision and high throughput. I will describe a new method we developed for characterizing the deformability and surface friction of cancer cells and will present recent progress on determining if this method can identify circulating tumor cells in cancer patient samples.

5:05 CTCs and Their Applications to Clinical Laboratories

Koh Furuta, M.D., Ph.D., Head, Clinical Laboratories, National Cancer Center Hospital

Ali Asgar Bhagat, Ph.D., Technical Director, R&D, Clearbridge BioMedics Pte Ltd

We utilized a prototype of CTC isolation device in collaboration with National Singapore University. This particular device can isolate CTCs on the microfluidic platform. We have successfully isolated CTCs derived from advanced colon cancer patients. A part of the isolated CTCs is utilized for biobanking and NGS.

5:35 Close of Conference Program


Day 1 | Day 2 | Day 3 | Download Brochure 

 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 MMTC Final Agenda 

Premier Sponsors:

Abbott Molecular 

 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large